Extended Therapy of Drotrecogin Alfa (Activated) 4 vs 7 Days Infusion
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether continued administration of Drotrecogin
Alfa (Activated) up to additional 72 hours - after the so far recommended 96 hour infusion
period - results in a more rapid resolution of hypotension in severe septic patients.